Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A randomized controlled trial.
Maturitas
; 167: 1-7, 2023 01.
Article
em En
| MEDLINE
| ID: mdl-36279690
ABSTRACT
BACKGROUND:
Urogenital atrophy affects >50â¯% of women after breast cancer (BC) and there is reluctance to use local estrogen for this group. Hormone-free therapies like intravaginal laser therapy and hyaluronic acid suppositories have been shown to produce symptom relief in women with BC and urogenital atrophy, but have not been tested against each other. The aim of this study was to compare these nonhormonal modalities in women with urogenital atrophy after BC in a randomized fashion. STUDYDESIGN:
We randomly assigned 43 women (aged 49-58â¯years, mean age 54â¯years) with urogenital atrophy and a history of BC to receive intravaginal laser therapy (2 courses within 1â¯month) or hyaluronic acid suppositories (3 times/week continuously for three months). The primary endpoint was score on the Vaginal Health Index after 3â¯months. Secondary endpoints were subjective bother on a numeric rating scale for all urogenital atrophy domains, quality of life, sexual health and pelvic organ prolapse symptoms using validated questionnaires.RESULTS:
Of the 43 women who participated, 22 were randomized to intravaginal laser therapy, and 21 to vaginal suppositories. At 3â¯months score on the Vaginal Health Index had improved significantly in both groups (pâ¯=â¯0.001), without a significant difference between treatment groups (pâ¯=â¯0.232). Significant improvement was also seen in both groups for subjective bother of urogenital atrophy, quality of life and sexual health, without significant differences between laser or hyaluronic acid therapy.CONCLUSIONS:
Both intravaginal laser therapy and hyaluronic acid suppositories are effective treatment options for women after BC suffering from urogenital atrophy. No difference was found between treatment regimens. CLINICALTRIALS gov identifier NCT03816735, https//clinicaltrials.gov/ct2/show/NCT03816735.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Vaginais
/
Neoplasias da Mama
/
Terapia a Laser
Limite:
Female
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article